Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma

Area of Science:

• Genetics
• Oncology
• Immunology

Background:

• The IKZF1 gene encodes a crucial transcription factor for B-cell development.
• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with variable patient prognoses.

Purpose of the Study:

• To investigate the association between the IKZF1 rs4132601 polymorphism and the clinical outcome of DLBCL patients.
• To determine if IKZF1 variants have prognostic significance in DLBCL.

Main Methods:

• Genotyping of the IKZF1 rs4132601 polymorphism in 218 DLBCL patients and 715 controls using a TaqMan assay.
• Analysis of progression-free survival (PFS) and overall survival (OS) rates based on genotype.
• Stratification of analysis by International Prognostic Index (IPI) risk groups and B-cell lymphoma subtype (GCB).

Main Results:

• No significant difference in genotype distribution between DLBCL patients and controls.
• Patients with the IKZF1 TT genotype had a lower 2-year PFS rate (54.3%) compared to G+ genotypes (68.6%).
• The IKZF1 rs4132601 polymorphism independently predicted PFS, with a stronger effect in low/intermediate IPI risk groups.
• GCB-type DLBCL patients with the TT genotype had significantly lower 5-year OS rates (19.6%) than those with G+ genotypes (56%).

Conclusions:

• The IKZF1 rs4132601 polymorphism is associated with clinical outcomes in DLBCL.
• This variant may serve as an independent prognostic marker for PFS and OS in specific DLBCL patient subgroups.
• These findings highlight the role of IKZF1 genetic variations in DLBCL pathogenesis and prognosis.